Day Range Key Metrics. All Listings. Previous Close Open Volume 77, Shares Out Mil 1, Market Cap 14, Dividend Yield , Key Statistics. Extra Items TTM , Price To Book Quarterly 2. Julia Wang Chief Financial Officer. Mark C. Hing Ling Chau Company Secretary. Anthony C. Hooper Non-Executive Director. Timothy Y.
Chen Non-Executive Independent Director. Michael J. Goller Non-Executive Independent Director. Latest News. Breakingviews Biotech is set for a geopolitical stress test , article with image January 12, Pete Sweeney December 16, Jennifer Hughes December 13, Business Beigene's cancer therapy meets late-stage study goal Biotech firm Beigene Ltd , Reuters May 21, Financials Income Statement.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients. About BeiGene BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a Reader Account, it's easy to send email directly to the contact for this release.
Sign up today for your free Reader Account!
ITOS is seeking a larger than usual life science IPO to advance its pipeline of treatment candidates for solid tumors and other cancers. The next data readout for its lead candidate is expected in the first half of , so that is likely the next major catalyst opportunity for the stock. The market opportunities for the types of cancers the firm is seeking to treat are extremely large, with the solid tumor market expected to reach several hundred billion dollars worldwide in the coming years.
This amount is within the typical range for biopharma IPOs, so it does not present an unreasonable valuation. The IPO appears to be worth considering for patient life science investors. Gain Insight and actionable information on U. Get started with a free trial! Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.
Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a day Free Trial. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it other than from Seeking Alpha. I have no business relationship with any company whose stock is mentioned in this article. Donovan Jones Marketplace. Commentary ITOS is seeking a larger than usual life science IPO to advance its pipeline of treatment candidates for solid tumors and other cancers.
This article was written by. Donovan Jones. Author of IPO Edge. While many privately-owned companies are eager to become publicly traded, not everyone is in a rush to get listed. According to a new data analysis published by the U. You must first attract the right partners and get them engaged. How To Invest In Startups Investing in startup companies can be a risky business, but it can also be a highly lucrative one.
With the rise of today's technology and many avenues of innovation, entrepreneurship is at an all-time high. Don't let yourself be fooled into thinking that only tech Thank you for subscribing! If you have any questions feel free to call us at ZING or email us at vipaccounts benzinga. Contribute Login Join.
Market Overview. Tickers, Articles and Keywords:. Saudi Arabian Movie Theater Chain Plans IPO: Report Monday, March 7, - pm Nearly four years after Saudi Arabia allowed movie theaters to reopen after being shuttered for 35 years, a locally based movie chain operator is seeking to become publicly traded. Wednesday, December 8, - pm While many privately-owned companies are eager to become publicly traded, not everyone is in a rush to get listed.
Beijing-based oncology biotech BeiGene ($BGNE) has priced its offer of million American Depositary Shares at $24 each, the top of the range to take in. BeiGene, Ltd. American Depositary Shares (BGNE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. BeiGene, Ltd. (BGNE) IPO - rchaz.xyz